The role of microparticles in chronic obstructive pulmonary disease

Toru Takahashi1–3
Hiroshi Kubo1

1Department of Advanced Preventive Medicine for Infectious Disease, Tohoku University Graduate School of Medicine, Sendai, Japan; 2Cellular and molecular lung biology research units, Institut de Recherches Cliniques de Montréal (IRCM), Montreal, Quebec, Canada; 3Department of Anesthesiology, Tohoku University Hospital, Sendai, Japan

Correspondence: Hiroshi Kubo
Department of Advanced Preventive Medicine for Infectious Disease, Tohoku University Graduate School of Medicine, 2-1 Seiryoumachi, Aobaku, Sendai, 980-8575, Japan
Tel +81 22 717 7184
Fax +81 22 717 7576
Email hkubo@med.tohoku.ac.jp

Abstract: Accumulating evidence suggests that cell injury in lung tissues is closely connected to disease progression in chronic obstructive pulmonary disease (COPD). Microparticles (MPs) are shed membrane vesicles that are released from platelets, leukocytes, red blood cells, and endothelial cells when these cells are activated or undergo apoptosis under inflammatory conditions. Based on increasing evidence that endothelial injury in the pulmonary capillary vasculature leads to lung destruction, and because cardiovascular diseases are the main cause of death among individuals with COPD, endothelial MPs (EMPs) are now receiving attention as potential biomarkers for COPD. There are eight types of EMPs which are defined by the presence of different endothelial markers on the cell membrane: vascular endothelial-cadherin; platelet endothelial cell adhesion molecule; melanoma cell adhesion molecule; E-selectin; CD51; CD105; von Willebrand factor; and CD143 EMPs. Vascular endothelial-cadherin, platelet endothelial cell adhesion molecule, and E-selectin EMPs are increased in patients with stable COPD and are further increased in patients with exacerbated COPD compared to non-COPD patients. In addition, the levels of these three EMPs in patients with stable COPD are significantly correlated with lung destruction and airflow limitation. These results indicate that endothelial injury is closely connected to the pathophysiology of COPD. Interestingly, the variations in the levels of the eight EMP subtypes were not identical with changes in patient condition. Although the clinical significance of the differences in these eight EMP subtypes remains unclear, evaluating the expression pattern of endothelial antigens on circulating MPs might predict the presence and degree of endothelial injury in COPD patients. In addition, circulating MPs are proposed to have several physiological functions in vivo, such as intercellular crosstalk; the increase in EMPs in COPD seems to play a role in the pathophysiology of this disease.

Keywords: COPD, exacerbation, apoptosis, endothelial activation, EMPs

Introduction
Chronic obstructive pulmonary disease (COPD) is a lung disease characterized by nearly irreversible lung destruction which results in airflow limitation.1 The severity of the disease is determined according to the degree of airflow limitation, which is measured using forced expiratory volume in one second (FEV1). However, there are several limitations in the use of FEV1 to evaluate the daily condition and disease progression of COPD patients. First, the sensitivity of FEV1 in evaluating daily condition is not high. Second, although both frequent exacerbation2–5 and bronchial hyperresponsiveness6 are associated with rapid FEV1 decline, FEV1 does not reflect these conditions. Third, clinical manifestations and radiological observations are variable among COPD patients even when the degree of airflow limitation is the same.7 For these reasons, new biomarkers for COPD are being sought.8

Number of times this article has been viewed
This article was published in the following Dove Press journal:
International Journal of COPD
27 March 2014

© 2014 Takahashi and Kubo. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/.
Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Accumulating evidence indicates that injured cells in the lung tissue are closely involved in the pathophysiology of COPD. In animal models, the administration of a vascular endothelial growth factor receptor inhibitor induced apoptosis of pulmonary capillary endothelial cells, leading to emphysematous changes. The number of apoptotic epithelial and endothelial cells is increased in emphysematous lungs compared with normal lungs. In addition, senescence of alveolar epithelial and endothelial cells is accelerated in patients with emphysema. Greater numbers of apoptotic lung cells are observed in lung tissues from COPD patients than in those from smokers without COPD. Furthermore, morphological and biochemical markers of autophagy are increased in the lungs of patients with COPD compared with normal lung tissue. These results indicate the importance of injured cells in the pathophysiology of lung destruction and COPD.

Activated or injured cells release chemical mediators, such as alarmins and microvesicles, into the circulation, and these mediators can potently modulate systemic immune responses. There are three major types of microvesicles, which are primarily distinguished by size: exosomes (40–100 nm), microparticles (MPs) (0.1–1.0 µm), and apoptotic bodies (1–3 µm). In this review, we focus on endothelium-derived MPs, which can be detected by their endothelial-specific antigens using fluorescence-activated cell sorting (FACS), and discuss their potential as biomarkers for COPD.

**MPs**

MPs are membrane vesicles that are released by budding or shedding from the plasma membrane of activated or injured cells in response to inflammation (Figure 1). MP release from platelets, red blood cells, endothelial cells, tumor cells, and leucocytes has been reported. Because MPs are shed membrane vesicles, the antigens expressed on the original cell are expressed on the membrane of the MPs. For example, CD144, CD31, and CD62E are expressed on endothelial cell-derived MPs, whereas CD31 and CD41 are expressed on platelet-derived MPs. Various stimuli, such as increased intracellular Ca²⁺ and the activation of protein kinase C (PKC) and purinergic receptors of adenosine triphosphate (ATP) such as the P₂X₇ and P₂Y receptors, increase the rate of MP release. The contents of MPs are also variable and can include nucleic acids, particularly messenger ribonucleic acid (mRNA) and microRNA, proteolytic enzymes such as metalloproteinases, tissue factors, and alarmins. Released MPs interact with their target cells by binding to the surface of the target cell via specific receptors, followed by direct fusion of the shedding vesicle with the plasma membrane of the target cell, endocytic uptake of the vesicle, and horizontal transfer of molecules and RNA to the target cell. MPs play many roles, including modulating the biological functions of cells. For example, during leukocyte activation and arrest, activated mast cells and platelets deliver chemoattractants to endothelial cells through circulating MPs. MPs also display proinflammatory and prothrombotic activities through the activation of Toll-like receptors and other signaling pathways. MPs are released from cells in response to various conditions or stimuli and may be heterogeneous.

**MPs and smoking**

Smoking is the most important risk factor for COPD. Cigarette smoke increases autophagy and induces apoptosis and...
necrosis in lung cells.\textsuperscript{40–42} Smoking increases the levels of circulating MPs. In vitro studies have demonstrated that cigarette smoke extract induces the release of tissue factor-positive MPs as well as MPs with proteolytic activity attributed to matrix metalloproteinase-14 (MMP-14) from human macrophages in vitro.\textsuperscript{43,44} Incubating pulmonary microvascular endothelial cells or aortic endothelial cells with cigarette smoke extract induces the release of CD31\textsuperscript{+}/CD41\textsuperscript{+} MPs and CD146\textsuperscript{+} MPs in vitro.\textsuperscript{40} Secondhand smoke exposure induces the rapid release of circulating CD144\textsuperscript{+} endothelial microparticles (EMPs), within a few hours.\textsuperscript{45} Other groups have reported that CD31\textsuperscript{+}/CD42b\textsuperscript{+} EMPs are increased in healthy active smokers and further increased in active smokers with emphysema compared with healthy non-smokers.\textsuperscript{46}

**MPs and oxidative stress**

Oxidative stress induced by cigarette smoke exposure or activated neutrophils and/or macrophages in response to infection is also involved in the pathophysiology of COPD.\textsuperscript{47,48} Oxidative stress induces MP release. H$_2$O$_2$ induces apoptosis in endothelial cells and the release of CD31\textsuperscript{+}/CD41\textsuperscript{+} or CD146\textsuperscript{+} MPs from aortic and pulmonary microvascular endothelial cells in vitro.\textsuperscript{40} Plasma levels of glutathione peroxidase, a marker of oxidative stress, are correlated with increased levels of platelet-, erythrocyte-, and endothelial-derived MPs independent of other factors involved in endothelial injury in patients with metabolic disease.\textsuperscript{49}

**MPs and infection**

Viral and/or bacterial infection was reported to be detected in up to 60\% of COPD exacerbation and has been found to be associated with a rapid decline in lung function.\textsuperscript{50,51} Several articles reported the impact of infections on circulating MPs,\textsuperscript{52–55} and the number of circulating MPs is significantly increased by infection. Therefore, the presence of airway infection may induce MP release in patients with COPD exacerbation.

**EMPs**

EMPs are released from injured endothelial cells during apoptosis and cellular activation.\textsuperscript{19,56,57} EMPs are defined by the surface expression of endothelial antigens, such as CD144 (vascular endothelial [VE]-cadherin), CD31 (platelet endothelial cell adhesion molecule [PECAM]-1), CD62e (E-selectin), CD146 (melanoma cell adhesion molecule [MCAM]), and CD51 (vitronectin) (Table 1 and Figure 2). Circulating EMP numbers are increased in patients with vascular disorders such as cardiovascular diseases,\textsuperscript{58–60} vasculitis,\textsuperscript{61,62} thrombosis,\textsuperscript{63,64} renal failure,\textsuperscript{65–67} hyperlipidemia,\textsuperscript{68} and metabolic syndrome.\textsuperscript{69,70} The increase in circulating EMPs reflects the degree of endothelial injury in such conditions (Table 2).

In vitro studies have demonstrated that different stimuli, such as tumor necrosis factor $\alpha$, H$_2$O$_2$, and cigarette smoke extract, induce the release of different types of EMPs from cultured endothelial cells. The pattern of EMP release in response to a specific stimulus differs depending on the type of endothelial cell.\textsuperscript{40} These observations suggest that different types of EMPs are released depending on the site of inflammation and the type of stimulus. Some clinical studies have compared two or more subtypes of EMPs in patients with specific diseases and observed differences in the types of released EMPs (Table 3). Although the clinical significance

<table>
<thead>
<tr>
<th>Table 1 Endothelial markers used for detecting EMPs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Expression</strong></td>
</tr>
<tr>
<td>CD31: PECAM-1</td>
</tr>
<tr>
<td>CD51: integrin $\alpha$V chain</td>
</tr>
<tr>
<td>CD62E: E-selectin</td>
</tr>
<tr>
<td>CD105: endoglin</td>
</tr>
<tr>
<td>CD143: ACE</td>
</tr>
<tr>
<td>CD144: VE-cadherin</td>
</tr>
<tr>
<td>CD146: MCAM</td>
</tr>
<tr>
<td>von Willebrand factor</td>
</tr>
</tbody>
</table>

**Abbreviations:** ECs, endothelial cells; EMPs, endothelial microparticles; ACE, angiotensin-converting enzyme; PECAM, platelet endothelial cell adhesion molecule; MCAM, melanoma cell adhesion molecule; VE, vascular endothelial.
of these differences in EMP release remains unclear, the pattern of increased EMPs may reflect differences in inflammatory stimuli and the activated site in vivo.

**VE-cadherin EMPs**

VE-cadherin EMPs are defined as CD144+ MPs. VE-cadherin is expressed only on endothelial cells and is therefore the most specific marker for endothelial cells.\(^7^1\) In contrast to PECAM-1 and MCAM, VE-cadherin is specifically located at adherence junctions.\(^7^2\) VE-cadherin has been proposed to function as a gatekeeper of endothelial junctions.\(^3^7,7^3\) VE-cadherin does not support leukocyte migration but instead might function as an obstacle to migrating cells. Changes in the localization of VE-cadherin are associated with neutrophil migration and increased vascular permeability.\(^7^4\) The release of VE-cadherin EMPs may reflect the structural destruction of the endothelium rather than the inflammatory condition of the lung.

**PECAM EMPs**

PECAM-1 (CD31) is concentrated at endothelial junctions and is also expressed on the surfaces of platelets, neutrophils, and subsets of lymphocytes. In contrast to VE-cadherin, PECAM-1 is located outside of the adherence junctions on endothelial cells.\(^7^2,7^5\) Platelet-specific antigens such as CD41 or CD42b are used to distinguish PECAM EMPs from platelet-derived MPs; PECAM EMPs are defined as CD31+/CD41− or CD42b− MPs. PECAM-1 is not used to detect leukocyte-derived MPs because its expression on leukocytes is too low.\(^7^6\) PECAM-1 is a signaling molecule that plays diverse roles in vascular biology, including the regulation of platelet function, angiogenesis, T-cell and B-cell activation, endothelial cell permeability, etc.

**Table 2 Numbers of circulating EMPs in various diseases**

<table>
<thead>
<tr>
<th></th>
<th>VE-cadherin EMPs</th>
<th>PECAM EMPs</th>
<th>E-selectin EMPs</th>
<th>MCAM EMPs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cardiovascular diseases</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>?</td>
</tr>
<tr>
<td>Acute ischemic stroke</td>
<td>↑(^*^)</td>
<td>?</td>
<td>?</td>
<td>?</td>
</tr>
<tr>
<td><strong>Renal diseases</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal failure</td>
<td>↑</td>
<td>↑</td>
<td>?</td>
<td>↑</td>
</tr>
<tr>
<td><strong>Respiratory diseases</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary hypertension</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>?</td>
</tr>
<tr>
<td>Obstructive sleep apnea</td>
<td>?</td>
<td>↑</td>
<td>↑</td>
<td>?</td>
</tr>
<tr>
<td><strong>Risk factor for cardiovascular diseases</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>?</td>
<td>↑</td>
<td>↑(^*^)</td>
<td>?</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>?</td>
<td>↑</td>
<td>?</td>
<td>?</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>↑</td>
<td>↑</td>
<td>?</td>
<td>?</td>
</tr>
<tr>
<td>Obesity</td>
<td>?</td>
<td>↑</td>
<td></td>
<td>?</td>
</tr>
<tr>
<td><strong>Systemic inflammatory diseases</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vasculitis</td>
<td>↑</td>
<td>?</td>
<td>?</td>
<td>↑</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>?</td>
<td>↑</td>
<td>?</td>
<td>?</td>
</tr>
<tr>
<td>Active thrombotic thrombocytopenic purpura</td>
<td>?</td>
<td>↑</td>
<td>↑</td>
<td>?</td>
</tr>
<tr>
<td>Antiphospholipid syndrome</td>
<td>?</td>
<td>↑</td>
<td>?</td>
<td>?</td>
</tr>
<tr>
<td>Subarachnoid hemorrhage</td>
<td>?</td>
<td>?</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Sepsis</td>
<td>?</td>
<td>↑</td>
<td>?</td>
<td>↑</td>
</tr>
<tr>
<td>Allograft rejection</td>
<td>?</td>
<td>↑</td>
<td>?</td>
<td>↑</td>
</tr>
</tbody>
</table>

**Notes:** ↑ means P<0.05 versus healthy control; ? means no previous report; * means in moderate to severe stroke.

**Abbreviations:** PECAM, platelet endothelial cell adhesion molecule; MCAM, melanoma cell adhesion molecule; VE, vascular endothelial; EMPs, endothelial microparticles.
and transmigration across the endothelium. Our in vitro study indicated that PECAM EMPs are released from pulmonary microvascular endothelial cells mainly in response to apoptosis induced by stimulation by H₂O₂ or cigarette smoke extract. In addition, a clinical study indicated that approximately 90% of PECAM EMPs also express annexin V in COPD and 60% of PECAM EMPs express annexin V in active smokers. Therefore, the released EMPs likely reflect the apoptosis of injured endothelial cells.

**MCAM EMPs**

MCAM EMPs are defined as CD146⁺ MPs. MCAM is an adhesion molecule found on endothelial cells that is involved in processes such as endothelial permeability, signaling transduction, cell migration, angiogenesis, and the immune response. MCAM is located outside of the adherence junctions; however, MCAM expression is not restricted to cell junctions and is detected on the apical side of cultured endothelial cells. MCAM has been detected not only on endothelial cells but also on other cell types such as ECs, melanoma cells, and immune cells.

### Table 3 Articles comparing two or more EMP subtypes in subjects with pathological conditions

<table>
<thead>
<tr>
<th>Condition</th>
<th>EMP subtypes</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>ST-elevation myocardial infarction</td>
<td>Patients with LAD infarctions versus those with other infarct-related arteries&lt;br&gt;VE-cadherin EMPs: no change&lt;br&gt;PECAM EMPs: ↑&lt;br&gt;Significant correlation&lt;br&gt;VE-cadherin EMPs: EF, not myocardium at risk&lt;br&gt;PECAM EMPs: myocardium at risk and EF</td>
<td>Atherosclerosis. 2012;221(1):226–231</td>
</tr>
<tr>
<td>Current smoker</td>
<td>Healthy non-smokers versus healthy smokers&lt;br&gt;PECAM EMPs: ↑&lt;br&gt;E-selectin EMPs: ↓ (CD42b CD62-L/CD42b CD31⁺ ratio)</td>
<td>Am J Respir Crit Care Med. 2011;184(2):224–232</td>
</tr>
<tr>
<td>End-stage renal disease</td>
<td>Significant correlation&lt;br&gt;VE-cadherin EMPs: brachial artery, ascending aortic SS&lt;br&gt;PECAM EMPs: brachial artery SS</td>
<td>Hypertension. 2007;49:902–908</td>
</tr>
<tr>
<td>Precapillary PH</td>
<td>PH patients versus control&lt;br&gt;VE-cadherin, PECAM, E-selectin EMPs: ↑&lt;br&gt;Significant correlation&lt;br&gt;VE-cadherin, PECAM EMPs: pulmonary pressure, CI&lt;br&gt;E-selectin EMPs: no correlation with pulmonary pressure, CI</td>
<td>Am J Respir Crit Care Med. 2008;177:1268–1275</td>
</tr>
<tr>
<td>Precapillary PH</td>
<td>PH patients who died or were re-admitted versus patients without events&lt;br&gt;VE-cadherin, PECAM EMPs: no change&lt;br&gt;E-selectin EMPs: ↑ (high E-selectin EMP level: high rate of clinical complications, worse prognosis)</td>
<td>J Heart Lung Transplant. 2009;28:1081–1086</td>
</tr>
<tr>
<td>Short-term withdrawal of CPAP in patients with obstructive sleep apnea</td>
<td>CPAP withdrawal group versus continuing therapeutic CPAP group&lt;br&gt;PECAM EMPs: no change&lt;br&gt;E-selectin EMPs: ↑ (in the CPAP withdrawal group)</td>
<td>Eur Respir J. 2009;33:574–580</td>
</tr>
<tr>
<td>Circulating EMPs in acute ischemic stroke</td>
<td>Moderate to severe ischemic stroke patients versus control&lt;br&gt;Endoglin + EMPs (E + EMPs): ↑&lt;br&gt;VE-cadherin + EMPs (C + EMPs): ↑&lt;br&gt;Phosphatidylserine + EMPs (PS + EMPs): ↑&lt;br&gt;iCAM-1 + EMPs (I + EMPs): ↑&lt;br&gt;Significant correlation&lt;br&gt;E + EMPs: brain ischemic lesion volume, discharge clinical outcome&lt;br&gt;PS + EMPs: brain ischemic lesion volume&lt;br&gt;I + EMPs: brain ischemic lesion volume&lt;br&gt;C + EMPs: discharge clinical outcome</td>
<td>J Thromb Haemost. 2006;4:1296–1302</td>
</tr>
<tr>
<td>COPD</td>
<td>Stable condition (versus control)&lt;br&gt;VE-cadherin, PECAM, E-selectin EMPs: ↑&lt;br&gt;MCAM EMPs: no change&lt;br&gt;Exacerbation (versus before exacerbation)&lt;br&gt;VE-cadherin, PECAM, E-selectin EMPs: ↑&lt;br&gt;MCAM EMPs: no change</td>
<td>Thorax. 2012;67:1067–1074</td>
</tr>
</tbody>
</table>

**Abbreviations:** LAD, left anterior descending coronary artery; ECs, endothelial cells; ACE, angiotensin-converting enzyme; PECAM, platelet endothelial cell adhesion molecule; MCAM, melanoma cell adhesion molecule; VE, vascular endothelial; EMPs, endothelial microparticles; EF, ejection fraction; SS, shear stress; PH, pulmonary hypertension; CI, cardiac index; CPAP, continuous positive airway pressure; COPD, chronic obstructive pulmonary disease.
Recent studies have indicated that the main causes of death with severe COPD are cardiovascular events such as ischemic heart diseases and stroke, not respiratory events. Vascular abnormalities in the endocardium in both the pulmonary and systemic vasculatures have been reported in COPD patients. Impaired endothelial function as assessed by flow-mediated dilation of the brachial artery is associated with low FEV1 in COPD. Subclinical arteriosclerosis, as evaluated by carotid intima-media thickness and focal atheroma plaque, is exaggerated early in the disease process of COPD. Reduced white matter integrity throughout the brain has been detected by magnetic resonance imaging in COPD patients, suggesting cerebral small vessel injury caused by COPD-associated conditions. The repair capacity of endothelial progenitor cells is also significantly impaired in the early stage of COPD. Furthermore, some animal studies have demonstrated apoptosis of pulmonary capillary endothelial cells due to emphysematous changes. These reports indicate that endothelial injury is closely connected to the pathophysiology of COPD.

We reported that VE-cadherin EMPs, PECAM EMPs, and E-selectin EMPs were significantly increased in patients with stable COPD compared to ex-smoker controls independent of smoking history, sex, body mass index, and age. This increase in PECAM EMPs was confirmed in a larger study performed by the MESA group. However, when adjusted for other factors, there were no significant differences in the levels of CD51 EMPs and E-selectin EMPs, although both EMPs tended to increase in COPD in the MESA group’s study. According to the Global initiative for chronic Obstructive Lung Disease (GOLD) stage progression, VE-cadherin EMPs, PECAM EMPs, and E-selectin EMPs were significantly increased in our study, although we could not analyze differences between each stage due to the small sample sizes. The MESA group reported that PECAM EMPs were significantly increased in mild and moderate COPD compared to control subjects in analyses adjusted for other factors; in contrast CD51 EMPs were not significantly elevated and E-selectin EMPs were only elevated in severe COPD. These results indicate that PECAM, VE-cadherin, and E-selectin EMPs are increased in patients with stable COPD compared to healthy controls independent of other factors associated with endothelial injury.

These two studies also examined the relationships between the degree of lung destruction and the numbers of EMPs. PECAM EMPs, E-selectin EMPs, and VE-cadherin EMPs were inversely correlated with parameters of lung functions such as the percent predicted FEV1. The MESA group also reported that PECAM EMPs were significantly associated with parameters of lung destruction such as
percent emphysema (low attenuation area; LAA), pulmonary microvascular perfusion as assessed by magnetic resonance imaging, and diffusion capacity of the lung for carbon monoxide ($D_{\text{LCO}}$). However, there was no significant correlation between E-selectin EMP levels and these parameters. By contrast, E-selectin EMPs were significantly related to hyperinflation characterized by both increased RV and a higher RV/TLC ratio; no such relationship was observed for PECAM EMPs. These results indicate that endothelial injury combined with impaired mobilization capacity of endothelial progenitor cells might be involved in the pathogenesis of emphysema and COPD.

Endothelial injury occurs in both the pulmonary and systemic vasculatures in COPD. Thus, EMPs can be released from both the pulmonary vasculatures and systemic vasculatures. To distinguish between EMPs originating from pulmonary and systemic circulation, the absence of vWF and the presence of angiotensin-converting enzyme (ACE; CD143) on EMPs were examined. vWF is a marker of endothelial cells that is not expressed on pulmonary capillary cells. Therefore, vWF-negative EMPs are of pulmonary capillary origin. The pulmonary capillary endothelium contains abundant ACE. Thus, ACE-positive EMPs are of pulmonary capillary origin. In active smokers with normal spirometry and low $D_{\text{LCO}}$, approximately 75% of PECAM EMPs were ACE positive, indicating pulmonary capillary origin. In stage II COPD patients, approximately 60% of the increased EMPs were vWF negative (Figure 3). In addition, the numbers of EMPs in stage IV COPD patients with severe emphysema were lower than those with mild emphysema, reflecting the reduction of pulmonary capillary vascular beds in emphysema. These results confirmed two facts. First, the increased EMPs in COPD mainly originate from the pulmonary capillary vasculature. Second, the numbers of vWF-negative or ACE-positive EMPs are sensitive markers for the detection of endothelial injury in the pulmonary capillary vasculature.

Multivariable analysis revealed that E-selectin levels were higher in patients with stable COPD with a history of frequent exacerbation (two or more episodes of exacerbation each year) than in COPD patients without frequent exacerbation. Unfortunately, the relationship between the number of EMPs and the rate of exacerbation was not analyzed in the MESA study. E-selectin EMP levels may reflect ongoing endothelial inflammation. Because exacerbations are associated with accelerated loss of lung function, we hypothesize that high E-selectin EMP levels led to a rapid loss of lung function in patients with stable COPD with a history of frequent exacerbation.

### Circulating EMPs in patients with exacerbated COPD

Recent studies have indicated that an exacerbation episode is connected to the progression of COPD. A history of frequent exacerbation and/or numbers of exacerbation episodes is associated with future rapid FEV1 decline, increased morbidity, readmission rates, and mortality. Exacerbation episodes are also associated with emphysema progression, as evaluated by chest computed tomography scans in patients with COPD. Although the importance of exacerbation in COPD management is becoming clearer, the diagnosis and evaluation of exacerbation are mainly based on clinical symptoms.
Accumulating evidence suggests that further endothelial injury occurs during exacerbation. For example, flow and nitroglycerin-mediated peripheral vascular dilation are impaired during acute exacerbation. In addition, inflammatory responses, particularly platelet activation, are upregulated during exacerbation. Platelet aggregation is exaggerated, mean platelet volume is increased, and plasma vWF and fibrinogen levels are increased during exacerbation. To clarify the influence of COPD exacerbation on the endothelium, we examined the numbers of EMPs during exacerbation.

VE-cadherin, PECAM, and E-selectin EMPs were significantly higher in patients during COPD exacerbation than in stable patients. Interestingly, the majority of the EMPs that were increased during COPD exacerbation were vWF negative (Figure 3), indicating that pulmonary capillary endothelial cells were the main targets of injury during exacerbation. In addition, exacerbation is associated with the progression of emphysema, which is connected to endothelial injury in the pulmonary vasculature. These reports confirmed that endothelial injury, primarily in pulmonary capillary endothelial cells, occurred during exacerbation.

The trends in the levels of circulating VE-cadherin EMPs, PECAM EMPs, and E-selectin EMPs differed after exacerbation (Figure 3). All EMP levels increased significantly one day after the onset of exacerbation, but after 28 days, the levels of VE-cadherin EMPs and PECAM EMPs remained high, while the level of E-selectin EMPs declined to less than the baseline level. The persistent high VE-cadherin and PECAM EMP levels after 28 days indicate that endothelial injury induced by exacerbation continues even after clinical symptoms disappear. Similar to E-selectin EMP levels, plasma fibrinogen levels also increase during exacerbation and decrease significantly in 4–6 weeks. Although there are no data to indicate a significant correlation between E-selectin EMP levels and plasma fibrinogen levels, these reports provide additional evidence that E-selectin EMP levels reflect ongoing endothelial inflammation and that VE-cadherin and PECAM EMP levels reflect endothelial injury as a consequence of endothelial inflammation. The decrease in the high E-selectin EMP levels during the early phase of exacerbation to levels lower than the baseline after treatment indicates that inflammation is present on the endothelium even during the stable phase before the onset of exacerbation. Most of the patients who underwent exacerbation received a systemic corticosteroid therapy; however, the role of steroid in the EMP levels is not defined yet. Further analyses are needed to clarify the impact of the COPD drugs on the kinetics of EMPs. Furthermore, drug therapies that ameliorate increased EMP levels may have an effect on prognosis of COPD patients.

**Effects of increased EMPs on COPD pathophysiology**

Increased numbers of EMPs are observed in patients with stable COPD. The release of EMPs increases further during exacerbation. In addition, COPD patients with a history of frequent exacerbation exhibit high levels of circulating EMPs not only during exacerbation but also in the stable phase. However, the effects of this increase in EMPs on COPD pathophysiology remain unclear. In patients with severe systemic inflammatory syndrome, EMPs are produced and actively bind to leukocytes. MPs from human atherosclerotic plaques promote transendothelial migration of monocytes. Circulating MPs in patients with myocardial infarction induce endothelial dysfunction. Based on these reports, the increased EMPs released from injured pulmonary endothelium might induce further endothelial injury in both the pulmonary vasculature and distant systemic vasculature; this injury might be involved in further lung destruction as well as the increased incidence of cardiovascular diseases in COPD patients in both the stable phase and after exacerbation. Because the MPs released in response to various stimuli are heterogeneous, future studies should examine the effects of MPs on the endothelium using MPs isolated from COPD patients. Prospective studies are also needed to clarify the relationship between increased EMP levels and the incidence of cardiovascular diseases.

**Technical difficulties with measuring EMPs**

There are several technical difficulties reported in the measurement of MPs. For example, there is no clear definition of MPs. The differences between exosomes and MPs remain unclear. Thus, there is no standard protocol for isolating and detecting circulating MPs from the plasma, and the results of microparticle studies are often inconsistent. Differences in flow cytometers influence the sensitivity of MP detection. In addition, differences in centrifugation protocols influence the number of MPs. Clear definitions and standardization of protocols are essential.

**Other remaining questions**

Although much evidence for a link between COPD and circulating EMPs has been documented, there are several issues to clarify in the future.
functions of the increased EMPs

- Proinflammatory?
- Prothrombotic activity?

therapy to reduce EMP levels

- Good prognosis?
- Reduce frequency of exacerbation?
- Slow down lung destruction?
- Decrease cardiovascular complications?

Firstly, the effects of increased EMPs on the pathophysiological condition or progression of exacerbation are not clear. MPs are not the passive parameter induced from activated or injured cells but rather active modulators that promote both pro-inflammatory and anti-inflammatory signals. 123 MPs contain proteins and microRNAs and have a capacity to deliver those components to distant endothelial cells. 22 Therefore, increased EMPs may influence vascular function and systemic inflammation under COPD exacerbation.

Secondly, the release of MPs originating from other cell types is not clearly evaluated in COPD patients. Other MPs, such as platelet-derived and leukocyte-derived MPs, play different roles in endothelial phenotypes; in particular, platelet-derived MPs are known to increase in cardiovascular diseases, including myocardial infarction. 126 Therefore, the role of other MPs in the comorbidity and the prognosis of COPD would be a great interest.

Lastly, epithelial-derived MPs in airways are not elucidated in COPD patients. Tissue factor-bearing MPs, which demonstrate procoagulant activity, are elevated in the pulmonary edema fluid of acute respiratory distress syndrome patients; 127 these MPs appear to be derived from alveolar epithelial cells. Similarly, epithelial injury present in COPD airways may produce the epithelial-derived MPs.

Conclusion

In this review, we proposed the potential use of circulating MPs, particularly EMPs, as novel biomarkers for COPD (Figure 4). In addition, by comparing subtypes of MPs that are increased in COPD patients, we may be able to reclassify heterogeneous COPD. Furthermore, the relationship between COPD and other MPs, such as platelet-derived MPs, could be an intriguing area of investigation in the future.

Disclosure

The authors report no conflicts of interest in this work.

References


